Hims & Hers Health Launches $49 Compounded Wegovy Pill Alternative

Hims & Hers Health, an online telehealth company, has announced that it will start offering a compounded version of the popular Wegovy weight loss pill for $49 per month. This price is about $100 less than the branded Wegovy pill, which is sold by Novo Nordisk for $149 per month.

The new product contains semaglutide, the same active ingredient as Wegovy. Hims & Hers is offering this as part of its range of weight loss solutions, aiming to provide customers with more affordable and accessible treatments. The treatment is a pill, providing an alternative to needles.

Following the announcement, the shares of pharmaceutical companies Novo Nordisk and Eli Lilly declined, while Hims & Hers saw a rise in its stock price. The offering has triggered reactions in the market due to its lower cost and easy online access.

A compounded drug is a medicine made by a pharmacist or doctor by combining or altering ingredients to fit the needs of a specific patient, rather than using a mass-produced standard version.

Hims & Hers is offering its compounded semaglutide pill for $49 per month, which is about $100 less than the $149 per month cost of the branded Wegovy pill.

Both companies sell branded weight loss medications. Hims & Hers introducing a much cheaper alternative led investors to worry about increased competition and possible impacts on their sales.

The new pill uses the same active ingredient (semaglutide) as Wegovy, but it is a compounded version and not the official branded product made by Novo Nordisk.

Reuters

Online telehealth company Hims and Hers Health will begin offering copies of Novo Nordisk's new Wegovy pill at an introductory price of $49 per month, the company said Thursday, about $100 less than the brand name.

Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. Thi...

CNBC

Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.

Forbes

Online pharmaceutical retailer Hims and Hers announced Thursday it will release a much cheaper, compounded version of the Wegovy weight loss pill just over half a year after Novo Nordisk caused its stock to collapse by terminating their distribution agreement out of concern for its mass-compounding...

Reuters

Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.

Market Watch

The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.

GlobeNewsWire

Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, inauthentic, and untested knockoff semaglutide pill. “The action by Hims & Hers is illegal mass com...

Reuters

Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an introductory price of $49 per month.

Reuters

Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers Health was launching a cut-price version of Novo's blockbuster Wegovy weight loss pill.

Proactive Investors

Hims & Hers (NYSE:HIMS) has announced the launch of a compounded semaglutide pill designed for weight loss, providing an alternative to Novo Nordisk (NYSE:NVO)'s Wegovy. The oral treatment uses the same active ingredient as Wegovy but is formulated to improve digestion and absorption, eliminating th...

WSJ

Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan.

Benzinga

Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.

Invezz

Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, Hims & Hers has undercut branded GLP-1 drugs by a wide margin, forcing investors to reassess the dur...

Investopedia

A new pill from Hims & Hers Health is rattling shares of leading weight-loss drugmakers.

The Motley Fool

Hims & Hers (HIMS 3.67%) introduced a new oral GLP-1 product this morning only weeks after Novo Nordisk's (NVO 8.16%) hit oral version of Wegovy hit the market. And the pharma giant wasn't happy with what they heard.

The Motley Fool

Novo Nordisk has launched its Wegovy GLP-1 drug in pill form. Amazon is getting into the fight, offering ease and low costs to customers who buy the Wegovy pill on its platform.

GlobeNewsWire

San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.

Reuters

Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month introductory price. Its shares ended down anyway.

Market Watch

Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.

CNBC

Online telehealth company Hims & Hers stock fell Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as little as $49, significantly lower than the $149 Novo sells the branded pill for.

Barrons

Shares in the Danish drugmaker have tanked this week, dragged down by a weak sales outlook and the launch of a Wegovy knockoff.

Proactive Investors

Citi has warned that Novo Nordisk (NYSE:NVO) inability to curb the use of compounded semaglutide may weigh on investor sentiment, despite the strength of its obesity drug portfolio. In a note following Novo's post-results meeting in London, analysts said the launch of a compounded semaglutide pill b...

Show All Sources